The global TB disease vaccine market was valued at USD 1.20 billion in 2025 and is estimated at USD 1.28 billion in 2026. The market is projected to reach USD 2.10 billion by 2034 at a 6.4% CAGR. The market combines established BCG vaccination demand with a developing pipeline of vaccines intended to improve protection against tuberculosis, particularly pulmonary disease in adolescents and adults.
Access the complete report: https://www.24lifesciences.com/tb-disease-vaccine-market-15213
Download segment insights: https://www.24lifesciences.com/download-sample/15213/tb-disease-vaccine-market
Emerging Trends Shaping Market Evolution
BCG remains the foundation of tuberculosis vaccination programs in many high-burden countries, while the research pipeline is expanding. The 24LifeSciences report highlights a late-stage development environment in which novel candidates must demonstrate efficacy, safety, manufacturability and affordability before broad adoption. Public procurement and international immunization programs remain important demand channels.
Key Market Drivers Supporting Growth
- Persistent global tuberculosis burden
- Continued BCG vaccination programs
- Development of next-generation TB vaccine candidates
- Public-health investment in infectious-disease prevention
- Need for stronger protection against adult and adolescent pulmonary TB
Access the complete report: https://www.24lifesciences.com/tb-disease-vaccine-market-15213
Download segment insights: https://www.24lifesciences.com/download-sample/15213/tb-disease-vaccine-market
Segment Insights & Regional Overview
The report covers prevention vaccines, post-exposure vaccines and other categories. Procurement channels include self-procurement and UNICEF-related demand, alongside other channels. Asia-Pacific is identified as the largest regional market in 2025, with Europe, North America, Latin America and the Middle East & Africa also covered.
Competitive Landscape: Key Companies
Merck & Co., Inc.; Japan BCG Laboratory; Serum Institute of India Pvt. Ltd.; AJ Vaccines; PT Bio Farma (Persero); GreenSignal Bio Pharma Pvt. Ltd.; China National Biotec Group; Biomed Lublin; Taj Pharmaceuticals; Fundação Ataulpho de Paiva; IVAC; Queen Saovabha Memorial Institute; Microgen.
Access the complete report: https://www.24lifesciences.com/tb-disease-vaccine-market-15213
Download segment insights: https://www.24lifesciences.com/download-sample/15213/tb-disease-vaccine-market
Strategic Outlook
The market outlook depends on the performance and regulatory progression of novel vaccine candidates as well as the continued procurement of BCG. Manufacturing scale, affordability and public-health adoption will be important determinants of future expansion.
Key Benefits of the 24LifeSciences Report
- Detailed market segmentation and application-level analysis
- Regional market assessment and forecast outlook
- Competitive landscape and company profiling
- Identification of growth drivers, trends and market opportunities
- Strategic insights for manufacturers, investors and healthcare decision-makers
Access the complete report: https://www.24lifesciences.com/tb-disease-vaccine-market-15213
Download segment insights: https://www.24lifesciences.com/download-sample/15213/tb-disease-vaccine-market
About 24LifeSciences
24LifeSciences provides market intelligence and strategic research covering pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare services and related life-science industries. Its research reports are designed to provide market sizing, forecasts, segmentation, regional analysis and competitive insights for business and strategic planning.
Website: https://www.24lifesciences.com
